UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2017

Minerva Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-36517 (Commission File Number) 26-0784194 (I.R.S. Employer Identification No.)

1601 Trapelo Road Suite 284 Waltham, MA (Address of principal executive offices)

02451 (Zip Code)

(Registrant's telephone number, including area code): (617) 600-7373 (Former name or former address, if changed since last report)

	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On March 16, 2017 and March 17, 2017, certain investors in Minerva Neurosciences, Inc.'s (the "Company") previously announced March 2015 private placement exercised their warrants. Upon exercise, the Company issued the investors an aggregate of 1,418,439 shares of the Company's common stock. The Company received gross proceeds of \$8,187,229.91 from the exercise prices of the exercised warrants.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MINERVA NEUROSCIENCES, INC.

By: /s/ Mark S. Levine

Name: Mark S. Levine

Title: Senior Vice President, General Counsel and Secretary

Date: March 21, 2017